drugset / Trial / NCT00002565

Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma

NCT00002565 ↗

RandomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective for intermediate-grade or immunoblastic non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens in treating patients who have intermediate-grade or immunoblastic non-Hodgkin's lymphoma.

Timeline

Start
1994-05-25
Primary completion
2007-02-05
Completion
2007-02-05

Drugs

EvaluationDrugModalityDoseRoute
Subject 2-MERCAPTOETHANESULFONIC ACID Small molecule — —
Subject Bleomycin Unknown — —
Subject Cisplatin Other / unclassified — —
Subject Cytarabine Small molecule — —
Subject Doxorubicin Other / unclassified — —
Subject Etoposide Small molecule — —
Subject Idarubicin Small molecule — —
Subject Ifosfamide Small molecule — —
Subject Methylprednisolone Other / unclassified — —
Subject Mitoxantrone Small molecule — —
Subject Prednisone Other / unclassified — —
Background Cyclophosphamide Other / unclassified — —
Background Vincristine Small molecule — —

Indications